Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corixa [CRXA] - cancer vaccines -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (39)	1/5/2001 1:16:20 PM
From: berblady	Read Replies (1) \| Respond to of 222

I think the smart guys at IDEC know what they're doing - a little (!) more so than the guys at CLTR. They also had the way cleared for them a bit by CLTR's fumbling around, which certainly wasn't pretty, but which may have been educational. As for the lead time being shortened, I think the jury is still out on that. Zevalin does have some toxicity issues which are a tad more serious than those of Bexxar. That may slow things down. If not, Zevalin will again gain from Bexxar's paving the way - this time on acceptance of a radiolabeled MAb. We (old CLTR holders) seem to be getting lost in CRXA's progress, or lack thereof.